XmAb541 (CLDN6 x CD3)
CD3 bispecific T-cell engager in Phase 1 development in combination with XmAb808 for CLDN6-expressing tumors
XmAb541 is an investigational, potential first-in-class CLDN6 x CD3 bispecific T-cell engager designed to redirect T cells to target and kill tumor cells expressing claudin-6 (CLDN6). XmAb541 incorporates Xencor’s XmAb® 2+1 bispecific antibody format, with two tumor-antigen binding domains and one T-cell binding domain. The multivalent format is intended to enable greater selectivity for CLDN6 over similar claudin family members, including CLDN9, CLDN3 and CLDN4.
Combination Development With XmAb808
Xencor is developing XmAb541 in combination with XmAb808, an investigational B7-H3 x CD28 bispecific antibody designed to provide tumor-targeted T-cell co-stimulation. Together, XmAb541 and XmAb808 are intended to provide complementary signals for T-cell activation: XmAb541 engages CD3 to direct T-cell killing of CLDN6-expressing tumor cells, while XmAb808 is designed to provide CD28 co-stimulation when bound to B7-H3-expressing tumor cells.
Preclinical findings presented at the American Association for Cancer Research Annual Meeting in April 2026 demonstrated co-expression of CLDN6 and B7-H3 on high-grade serous ovarian carcinoma cells. In preclinical studies, XmAb808 promoted durable T-cell-directed killing of cancer cells with XmAb541, enhanced XmAb541-induced killing by exhausted T cells and enhanced its anti-tumor activity. The low overlap of CLDN6 and B7-H3 expression on normal tissues may help localize T-cell co-stimulation to tumor cells, supporting clinical evaluation of the combination.
Clinical Evaluation
Xencor is conducting a Phase 1 dose-escalation study of XmAb541 in combination with XmAb808 in patients with CLDN6-expressing tumors, including high-grade serous ovarian carcinoma. (Clinicaltrials.gov: NCT06276491)
XmAb541 monotherapy expansion cohorts in high-grade serous ovarian carcinoma and germ cell tumors are expected to complete enrollment by the end of 2026, with data intended to support further combination development with XmAb808. (Clinicaltrials.gov: NCT07593092)
In July 2026, the FDA granted Fast Track designation to XmAb541 for the treatment of patients with germ cell tumors who have relapsed following two or more lines of platinum therapy or were refractory to prior platinum therapy.
XmAb® 2+1 Bispecific Antibodies
Selectively targeting tumor antigens can be challenging when those antigens are also expressed on normal tissues. Xencor’s XmAb 2+1 bispecific antibody format incorporates two tumor-antigen binding domains and one T-cell binding domain. This multivalent design is intended to enable more avid binding to—and selective killing of—tumor cells with higher antigen density, potentially sparing normal cells with lower antigen expression.
Xencor’s XmAb Bispecific Fc Domain provides the scaffold for these binding domains, maintaining full-length antibody properties and supporting production and purification using standard antibody manufacturing methods.
The XmAb 2+1 bispecific antibody format may be a particularly powerful tool for developing drug candidates against solid tumors. XmAb 2+1 bispecific antibodies include XmAb819 (ENPP3 x CD3), XmAb808 (B7-H3 x CD28) and XmAb541 (CLDN6 x CD3), in addition to several programs being developed by partners.
